The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
C-CAMP–Imperial College London partnership to boost biotech research, startup exchange, and translational innovation through a five-year collaboration
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
Subscribe To Our Newsletter & Stay Updated
